Table 3.

A summary of the reporting by ethnicity through different stages of COVID-19 clinical trials, including those approached, screened and deemed eligible or ineligible for inclusion; those enrolled in the trial; those followed up at the primary end point and longest follow-up; and reporting of effect estimates

Stage of trial	No. of trials reporting by ethnicity (no. participants)	References	No. of trials reporting as “White”, “BAME”, “non-white”, “Other” (no. participants)	References
Approached for inclusion	0		0
Screened for inclusion	0		7 (60,179)	[8, 10, 13, 17, 18, 23, 26]
Eligible for inclusion	0		7 (60,179)	[8, 10, 13, 17, 18, 23, 26]
Ineligible for inclusion	0		7 (60,179)	[8, 10, 13, 17, 18, 23, 26]
Enrolled in trial	17 (52,747)	[1–4, 6, 7, 12, 14–16, 19, 20, 24, 25, 27–29]	11 (64,722)	[5, 8–11, 13, 17, 18, 23, 26, 30]
Followed up at primary endpoint	0		9 (64,434)	[8–11, 13, 17, 18, 23, 26]
Followed up at longest follow-up	0		0
Effect estimates	0		11 (79,740)	[1, 8–11, 13, 17–19, 23, 26]